ONC

SEC source: 0001651308-21-000092 · wf-form4_162085153052240.xml · nonDerivative · entry 7

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,294

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected solely to cover the exercise cost and satisfy tax obligations for the share options that were exercised.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $299.00 to $299.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000092 · wf-form4_162085153052240.xml · nonDerivative · entry 6

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,394

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001651308-21-000092 · wf-form4_162085153052240.xml · nonDerivative · entry 1

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,747,271

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001651308-21-000080 · wf-form4_162024759149920.xml · nonDerivative · entry 4

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person on April 30, 2018. 1/5th of the securities will vest on each anniversary of April 30, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · derivative · entry 9

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 246,575

Underlying: Ordinary Shares · 19,500 shares

Expires 2026-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F9 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.

SEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 8

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.55 to $358.69, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 7

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.07 to $356.47, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 6

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.74 to $355.49, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 5

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 900

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.47 to $354.30, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 4

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $352.28 to $353.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 3

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

SEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 2

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001651308-21-000054 · wf-form4_161722357015596.xml · derivative · entry 8

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 266,075

Underlying: Ordinary Shares · 19,500 shares

Expires 2026-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F9 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.

SEC source: 0001651308-21-000054 · wf-form4_161722357015596.xml · nonDerivative · entry 7

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $326.26 to $326.36, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000054 · wf-form4_161722357015596.xml · nonDerivative · entry 6

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 227

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.19 to $325.93, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000054 · wf-form4_161722357015596.xml · nonDerivative · entry 5

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 427

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.85 to $324.38, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000054 · wf-form4_161722357015596.xml · nonDerivative · entry 4

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 805

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.63 to $323.56, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000054 · wf-form4_161722357015596.xml · nonDerivative · entry 3

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.58 to $322.41, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000054 · wf-form4_161722357015596.xml · nonDerivative · entry 2

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001651308-21-000049 · wf-form4_161592667190254.xml · nonDerivative · entry 1

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,827,829

F1 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5.

SEC source: 0001651308-21-000044 · wf-form4_161472191711486.xml · derivative · entry 8

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,575

Underlying: Ordinary Shares · 19,500 shares

Expires 2026-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.

SEC source: 0001651308-21-000044 · wf-form4_161472191711486.xml · nonDerivative · entry 7

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.86 to $322.80, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000044 · wf-form4_161472191711486.xml · nonDerivative · entry 6

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.70 to $321.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000044 · wf-form4_161472191711486.xml · nonDerivative · entry 5

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.28 to $320.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000044 · wf-form4_161472191711486.xml · nonDerivative · entry 4

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

SEC source: 0001651308-21-000044 · wf-form4_161472191711486.xml · nonDerivative · entry 3

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

SEC source: 0001651308-21-000044 · wf-form4_161472191711486.xml · nonDerivative · entry 2

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001651308-21-000024 · wf-form4_161230257593822.xml · derivative · entry 11

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,075

Underlying: Ordinary Shares · 19,500 shares

Expires 2026-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F8 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.

SEC source: 0001651308-21-000024 · wf-form4_161230257593822.xml · nonDerivative · entry 10

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.23 to $331.69, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000024 · wf-form4_161230257593822.xml · nonDerivative · entry 9

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

SEC source: 0001651308-21-000024 · wf-form4_161230257593822.xml · nonDerivative · entry 8

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

SEC source: 0001651308-21-000024 · wf-form4_161230257593822.xml · nonDerivative · entry 7

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

SEC source: 0001651308-21-000024 · wf-form4_161230257593822.xml · nonDerivative · entry 6

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.45 to $322.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000024 · wf-form4_161230257593822.xml · nonDerivative · entry 5

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 800

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

SEC source: 0001651308-21-000024 · wf-form4_161230257593822.xml · nonDerivative · entry 4

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 807

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.26 to $319.96, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000024 · wf-form4_161230257593822.xml · nonDerivative · entry 3

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.20 to $319.02, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000024 · wf-form4_161230257593822.xml · nonDerivative · entry 2

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001651308-21-000011 · wf-form4_161109386344448.xml · derivative · entry 9

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 649,000

Underlying: Ordinary Shares · 163,800 shares

Expires 2025-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F8 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 15, 2016, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon a sale event or certain termination events.

SEC source: 0001651308-21-000011 · wf-form4_161109386344448.xml · nonDerivative · entry 7

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $345.30 to $345.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000011 · wf-form4_161109386344448.xml · nonDerivative · entry 6

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,606

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.00 to $344.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000011 · wf-form4_161109386344448.xml · nonDerivative · entry 5

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001651308-21-000011 · wf-form4_161109386344448.xml · derivative · entry 8

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 812,800

Underlying: Ordinary Shares · 18,200 shares

Expires 2025-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F8 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 15, 2016, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon a sale event or certain termination events.

SEC source: 0001651308-21-000011 · wf-form4_161109386344448.xml · nonDerivative · entry 4

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $345.15 to $345.155, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000011 · wf-form4_161109386344448.xml · nonDerivative · entry 3

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.11 to $344.455, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-21-000011 · wf-form4_161109386344448.xml · nonDerivative · entry 2

Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001638599-21-000037 · doc4_6976.xml · nonDerivative · entry 8

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,699,954

F10 · shares: 667 and Life Sciences pursuant to an underwriting agreement with an underwriter sold 10,060 and 111,094 ADS at a price of $220.50 per ADS (net of underwriting discounts), respectively, to the underwriter as a result of the underwriter's exercise of its option to purchase additional ADS on December 30, 2020 that closed on January 4, 2021.

F1 · ownership.nature: American Depositary Shares ("ADS") of BeiGene, Ltd. (the "Issuer") each represent 13 Ordinary Shares ("Ordinary Shares") of the Issuer.

F7 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Baker Brothers Life Sciences, L.P, ("Life Sciences", and together with 667, the "Funds"), Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: 667 and Life Sciences pursuant to an underwriting agreement with an underwriter sold 10,060 and 111,094 ADS at a price of $220.50 per ADS (net of underwriting discounts), respectively, to the underwriter as a result of the underwriter's exercise of its option to purchase additional ADS on December 30, 2020 that closed on January 4, 2021.

SEC source: 0001638599-21-000037 · doc4_6976.xml · nonDerivative · entry 7

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 968,943

F10 · shares: 667 and Life Sciences pursuant to an underwriting agreement with an underwriter sold 10,060 and 111,094 ADS at a price of $220.50 per ADS (net of underwriting discounts), respectively, to the underwriter as a result of the underwriter's exercise of its option to purchase additional ADS on December 30, 2020 that closed on January 4, 2021.

F1 · ownership.nature: American Depositary Shares ("ADS") of BeiGene, Ltd. (the "Issuer") each represent 13 Ordinary Shares ("Ordinary Shares") of the Issuer.

F6 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: 667 and Life Sciences pursuant to an underwriting agreement with an underwriter sold 10,060 and 111,094 ADS at a price of $220.50 per ADS (net of underwriting discounts), respectively, to the underwriter as a result of the underwriter's exercise of its option to purchase additional ADS on December 30, 2020 that closed on January 4, 2021.

SEC source: 0001651308-20-000238 · wf-form4_160936407998605.xml · derivative · entry 9

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 324,575

Underlying: Ordinary Shares · 19,500 shares

Expires 2026-09-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F10 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.

SEC source: 0001651308-20-000238 · wf-form4_160936407998605.xml · nonDerivative · entry 8

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.28 to $253.18, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-20-000238 · wf-form4_160936407998605.xml · nonDerivative · entry 7

Huang Jane · CIK 0001683913 · CMO, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.15 to $252.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.